Standard
Therapeutic Vaccination Targeting Indoleamine-2, 3 Dioxygenase (IDO) Using a IDO Derived Class I Restricted Peptide in Combination with Aldara and Montanide for Patients With Locally Advanced or Metastatic Non Small-Cell Lung Cancer. A First-in-man Phase I Trial. / Buch-Hansen, Trine Zeeberg; Sørensen, Rikke Bæk; Mellemgaard, A.; Straten, P.T.; Andersen, M.H.; Svane, I.M.; Andersen, M.H.
I:
Journal of Immunotherapy, Bind 33, Nr. 8, 2010, s. 919-920.
Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › fagfællebedømt
Harvard
Buch-Hansen, TZ, Sørensen, RB, Mellemgaard, A, Straten, PT, Andersen, MH, Svane, IM & Andersen, MH 2010, 'Therapeutic Vaccination Targeting Indoleamine-2, 3 Dioxygenase (IDO) Using a IDO Derived Class I Restricted Peptide in Combination with Aldara and Montanide for Patients With Locally Advanced or Metastatic Non Small-Cell Lung Cancer. A First-in-man Phase I Trial', Journal of Immunotherapy, bind 33, nr. 8, s. 919-920.
APA
Buch-Hansen, T. Z., Sørensen, R. B., Mellemgaard, A., Straten, P. T., Andersen, M. H., Svane, I. M., & Andersen, M. H. (2010). Therapeutic Vaccination Targeting Indoleamine-2, 3 Dioxygenase (IDO) Using a IDO Derived Class I Restricted Peptide in Combination with Aldara and Montanide for Patients With Locally Advanced or Metastatic Non Small-Cell Lung Cancer. A First-in-man Phase I Trial. Journal of Immunotherapy, 33(8), 919-920.
Vancouver
Buch-Hansen TZ, Sørensen RB, Mellemgaard A, Straten PT, Andersen MH, Svane IM o.a. Therapeutic Vaccination Targeting Indoleamine-2, 3 Dioxygenase (IDO) Using a IDO Derived Class I Restricted Peptide in Combination with Aldara and Montanide for Patients With Locally Advanced or Metastatic Non Small-Cell Lung Cancer. A First-in-man Phase I Trial. Journal of Immunotherapy. 2010;33(8):919-920.
Author
Buch-Hansen, Trine Zeeberg ; Sørensen, Rikke Bæk ; Mellemgaard, A. ; Straten, P.T. ; Andersen, M.H. ; Svane, I.M. ; Andersen, M.H. / Therapeutic Vaccination Targeting Indoleamine-2, 3 Dioxygenase (IDO) Using a IDO Derived Class I Restricted Peptide in Combination with Aldara and Montanide for Patients With Locally Advanced or Metastatic Non Small-Cell Lung Cancer. A First-in-man Phase I Trial. I: Journal of Immunotherapy. 2010 ; Bind 33, Nr. 8. s. 919-920.
Bibtex
@article{fbdc7d910baa4a6d9c0116e0e29b280c,
title = "Therapeutic Vaccination Targeting Indoleamine-2, 3 Dioxygenase (IDO) Using a IDO Derived Class I Restricted Peptide in Combination with Aldara and Montanide for Patients With Locally Advanced or Metastatic Non Small-Cell Lung Cancer. A First-in-man Phase I Trial",
author = "Buch-Hansen, {Trine Zeeberg} and S{\o}rensen, {Rikke B{\ae}k} and A. Mellemgaard and P.T. Straten and M.H. Andersen and I.M. Svane and M.H. Andersen",
year = "2010",
language = "English",
volume = "33",
pages = "919--920",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams & Wilkins",
number = "8",
}
RIS
TY - ABST
T1 - Therapeutic Vaccination Targeting Indoleamine-2, 3 Dioxygenase (IDO) Using a IDO Derived Class I Restricted Peptide in Combination with Aldara and Montanide for Patients With Locally Advanced or Metastatic Non Small-Cell Lung Cancer. A First-in-man Phase I Trial
AU - Buch-Hansen, Trine Zeeberg
AU - Sørensen, Rikke Bæk
AU - Mellemgaard, A.
AU - Straten, P.T.
AU - Andersen, M.H.
AU - Svane, I.M.
AU - Andersen, M.H.
PY - 2010
Y1 - 2010
M3 - Conference abstract in journal
VL - 33
SP - 919
EP - 920
JO - Journal of Immunotherapy
JF - Journal of Immunotherapy
SN - 1524-9557
IS - 8
ER -
